Winton Group’s Adverum Biotechnologies ADVM Stock Holding History

Winton Group’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,342	Closed	-$270K	–	1382
2019 Q4	$270K	Buy	+2,342	New	+$206K	﹤0.01%	1382

Other funds holding ADVM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Winton Group's ADVM Position: Q1 2020 in Review

Winton Group sold out of Adverum Biotechnologies (ADVM) in Q1 2020, closing a stake of 2,342 shares — an estimated $270K sold.

Winton Group first reported a position in ADVM in Q4 2019 and held it in 1 quarter. The position peaked at $270K in Q4 2019. 126 funds tracked by Wall St. Rank hold ADVM as of Q1 2020.

Winton Group reported no remaining Adverum Biotechnologies position as of Q1 2020 after selling out during the quarter.
Winton Group sold 2,342 Adverum Biotechnologies shares in Q1 2020, an estimated $270K.
Winton Group first reported a position in Adverum Biotechnologies in Q4 2019 and held it in 1 quarter.
Winton Group's Adverum Biotechnologies position peaked at $270K in Q4 2019.
126 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2020.

Based on Winton Group's 13F filing for Q1 2020, filed 11 May 2020.